Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Neuroscience Letters

Volumn 206, Issue 1, 1996, Pages 37-40

  McNaught, Kevin St P ^a   Thull, Ulrike ^b   Carrupt, Pierre Alain ^b   Altomare, Cosimo ^c   Cellamare, Saverio ^c   Carotti, Angelo ^c   Testa, Bernard ^b   Jenner, Peter ^a   Marsden, C David ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BARI   (Italy)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

1,2,3,4 Tetrahydroisoquinoline; 1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 1 Methyl 4 phenylpyridinium; Complex I; Dopamine re uptake system; Dopaminergic cells; Parkinson's disease; PC12 cells

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ISOQUINOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT;

EID: 0029965262     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3940(96)12419-8     Document Type: Article

References (20)

1. Hartley, A., Stone, J.M., Heron, C., Cooper, J.M. and Schapira, A.H.V., Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease, J. Neurochem., 63 (1994) 1987-1990.
2. +) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake, Eur. J. Pharmacol., 166 (1989) 65-74.
3. Maruyama, W., Takahashi, T., Minami, M., Takahashi, A., Dostert, P., Nagatsu, T. and Naoi, M., Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. In H. Narabayashi, T. Nagatsu, H. Yanagisawa and Y. Mizuno (Eds.), Advances in Neurology, Vol. 60, Raven Press, New York, 1993, pp. 224-230.
4. McNaught, K.St.P., Thull, U., Carrupt, P.A., Altomare, C., Cellamare, S., Carotti, A., Testa, B., Jenner, P. and Marsden, C.D., Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Biochem. Pharmacol., 50 (1995) 1903-1911.
5. McNaught, K.St.P., Altomare, C., Cellamare, S., Carotti, A., Thull, U., Carrupt, P.A., Testa, B., Jenner, P. and Marsden, C.D., Inhibition of α-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), NeuroReport, 6 (1995) 1105-1108.
6. McNaught, K.St.P., Altomare, C., Cellamare, S., Carotti, A., Thull, U., Carrupt, P.-A., Testa, B., Jenner, P. and Marsden, C.D., Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on mitochondrial respiration, Biochem. Pharmacol., (1996) in press.
7. 3H]dopamine into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Biochem, Pharmacol., (1996) submitted.
8. Mizuno, Y., Matuda, S., Yoshino, H., Mon, H., Hattori, N. and Ikebe, S., An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease, Ann. Neurol., 35 (1994) 204-210.
9. Mizuno, Y., Saitoh, T. and Sone, N., Inhibition of mitochondrial α-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion, Biochem. Biophys. Res. Commun., 143 (1987) 971-976.
10. Nagatsu, T. and Yoshida, M., An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions, Neurosci. Lett., 87 (1987) 178-182.
11. Nicklas, W.J., Vyas, I. and Heikkila, R.E., Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridinium, a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Life Sci., 36 (1985) 2503-2508.
12. +) destroys cultured mesencephalic dopamine neurons, Biogenic Amines, 8 (1991) 61-67.
13. +) and tetrahydroisoquinoline derivatives on dopaminergic neurons in ventral mesencephalic striatal co-culture, Neurodegeneration, 3 (1994) 33-42.
14. Ogawa, M., Araki, M., Nagatsu, I., Nagatsu, T. and Yoshida, M, The effects of 1,2,3,4-tetrahydroisoquinolines (TIQ) on mesenchephalic dopaminergic neurones in C57BL/6J mice; immunohistochemical studies: tyrosine hydroxylase, Biogenic Amines, 6 (1989) 427-436.
15. Perry, T.L., Jones, K. and Hansen, S., Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice, Neurosci. Lett., 85 (1988) 101-104.
16. 1 reductase (complex I) deficiency in Parkinson's disease, J. Neurochem., 55 (1990) 2142-2145.
17. Suzuki, K., Mizuno, Y. and Yoshida, M., Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain, Neurochem. Res., 7 (1990) 705-710.
18. Suzuki, K., Mizuno, Y., Yasuhiro, Y., Nagatsu, T. and Mitsuo, Y., Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain, J. Neurol. Sci., 109 (1992) 219-223.
19. Yoshida, M., Niwa, T. and Nagatsu, T., Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioural and biochemical changes, Neurosci. Lett., 119 (1990) 109-113.
20. Yoshida, M., Ogawa, M., Suzuki, K. and Nagatsu, T., Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. In H. Narabayashi, Yanagisawa and Y. Mizuno (Eds.), Advances in Neurology, Vol. 60, Raven Press, New York, 1993, pp. 207-211.